<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910231</url>
  </required_header>
  <id_info>
    <org_study_id>2012P000638</org_study_id>
    <nct_id>NCT03910231</nct_id>
  </id_info>
  <brief_title>The Role of Vasopressin Antagonism on Renal Sodium Handling</brief_title>
  <official_title>The Role of Vasopressin Antagonism on Renal Sodium Handling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasopressin has primarily been considered to be a water and osmosis regulating hormone that
      mediates its effects on renal aquaporin channels. Recent data suggest that vasopressin,
      through its V2 receptor, may also modulate sodium homeostasis. The purpose of this human
      physiology study was to test whether antagonism of the V2R alters urine sodium excretion in
      normal healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vasopressin's potential roles in maintaining normal volume homeostasis are expanding. While
      previous data support the concept that vasopressin's primary role is in mediating water
      homeostasis, recent data suggest that vasopressin, through its V2 receptor, may also modulate
      sodium homeostasis. This effect occurs via activation of the epithelial sodium channel
      (ENaC). These studies document that vasopressin via activation of the V2 receptor, not only
      reduces free water excretion but also sodium excretion. These data suggest that blocking this
      receptor under the right circumstances and in the right population may be effective in
      modulating hypertension in humans: specifically a V2 receptor antagonist may be effective in
      treating some individuals that have salt-sensitive hypertension. The current proposal will
      test in normal human subjects the proof of principle of the above stated hypothesis, and to
      assess the best markers to determine such an effect. It is important to perform studies with
      strict environmental control in a clinical research center because of the variability of
      environmental factors that can create confusion in interpreting data (dietary sodium,
      activity, body posture, diurnal variation, ambient temperature, sleep-wake cycle, etc.).

      The overall program objective is to determine if a vasopressin V2 antagonist will be an
      effective treatment for salt-sensitive hypertension and if so, what subtype. The object of
      this specific proposal is to determine the effect of a selective V2 antagonist on sodium
      handling in normal subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2012</start_date>
  <completion_date type="Actual">February 1, 2015</completion_date>
  <primary_completion_date type="Actual">September 30, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, double-blinded, parallel arm clinical trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blinding to investigator, participant and study staff. Randomization assignment and blinding provided by Investigational Drug Services</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Acute intravenous saline response</measure>
    <time_frame>6 hours</time_frame>
    <description>Urine sodium excretion measured in response to saline infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary salt response</measure>
    <time_frame>6 days</time_frame>
    <description>Cumulative sodium excretion measured in response to dietary salt loading</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15mg Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg Tolvaptan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30mg Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg Tolvaptan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan Oral Tablet</intervention_name>
    <description>Tolvaptan, to block V2R</description>
    <arm_group_label>15mg Tolvaptan</arm_group_label>
    <arm_group_label>30mg Tolvaptan</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Blood pressure &lt;130/85 mmHg and &gt;100/50 mmHg

          -  Normal laboratory values for (see &quot;Normal Values&quot; table):

          -  Complete blood count

          -  Serum creatinine, sodium, potassium, glucose, liver enzymes

          -  Urinalysis

          -  ECG

        Exclusion Criteria:

          -  - Alcohol intake &gt;12 oz per week

          -  Tobacco or recreational drug use

          -  History of coronary disease, diabetes, hypertension, stroke, kidney disease, or
             illness requiring overnight hospitalization in the past 6 months

          -  Any prescription medication or herbal medication use except oral contraceptive or
             multivitamin

          -  Pregnancy or current breastfeeding

          -  First degree relative with hypertension, diabetes, stroke, renal or cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan S Williams, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Stockand JD. Vasopressin regulation of renal sodium excretion. Kidney Int. 2010 Nov;78(9):849-56. doi: 10.1038/ki.2010.276. Epub 2010 Aug 25. Review.</citation>
    <PMID>20736986</PMID>
  </reference>
  <reference>
    <citation>Bankir L, Bichet DG, Bouby N. Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? Am J Physiol Renal Physiol. 2010 Nov;299(5):F917-28. doi: 10.1152/ajprenal.00413.2010. Epub 2010 Sep 8. Review.</citation>
    <PMID>20826569</PMID>
  </reference>
  <reference>
    <citation>Blanchard A, Frank M, Wuerzner G, Peyrard S, Bankir L, Jeunemaitre X, Azizi M. Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent. Clin J Am Soc Nephrol. 2011 Apr;6(4):753-9. doi: 10.2215/CJN.06540810. Epub 2011 Jan 13.</citation>
    <PMID>21233458</PMID>
  </reference>
  <reference>
    <citation>Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003 Jun 3;107(21):2690-6. Epub 2003 May 12.</citation>
    <PMID>12742979</PMID>
  </reference>
  <reference>
    <citation>Hauptman PJ, Zimmer C, Udelson J, Shoaf SE, Mallikaarjun S, Bramer SL, Orlandi C. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol. 2005 Nov;46(5):609-14.</citation>
    <PMID>16220067</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jonathan S. Williams, MD, MMSc</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vasopressin receptor</keyword>
  <keyword>renal sodium excretion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>October 2019 for 1 year</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

